The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Nonfasting Remnant Cholesterol in a Real World Population.
Anthony P MoriseJennifer TennantSari D HolmesDanyel H TackerPublished in: Journal of lipids (2018)
In patients receiving PCSK9 inhibitors, remnant cholesterol as determined from nonfasting blood was reduced in proportion to pretreatment triglycerides.
Keyphrases